Advarra, the market leader in regulatory reviews and a leading provider of clinical research technology, today announced the ...

The platform’s architecture allows it to handle everything from small single-site pilot trials to complex multi-phase ...

LabConnect, a leading global provider of central laboratory services today announced plans to form a strategic collaboration ...

Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients – – Gemini could potentially ...

Generative artificial intelligence (AI) has absolutely exploded onto the scene. It's become a top strategic priority in the ...

Mayo Clinic researchers have developed a new way to predict whether existing drugs could be repurposed to treat heart failure ...

ABBOTT PARK, Ill., April 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving ...

A majority of cancer drugs approved in the US during 2019-2022 had “clinical trial uncertainties,” research suggests.

Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and ...